Kidney Fibrosis – Pipeline Review, H1 2018

Global Markets Direct’s, ‘Kidney Fibrosis – Pipeline Review, H1 2018’, provides an overview of the Kidney Fibrosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Kidney Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Kidney Fibrosis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Kidney Fibrosis

– The report reviews pipeline therapeutics for Kidney Fibrosis by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Kidney Fibrosis therapeutics and enlists all their major and minor projects

– The report assesses Kidney Fibrosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Kidney Fibrosis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Kidney Fibrosis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Kidney Fibrosis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AdAlta Ltd

Angion Biomedica Corp

BiOrion Technologies BV

Cellmid Ltd

Epigen Biosciences Inc

Evotec AG

Galectin Therapeutics Inc

Genzyme Corp

Isarna Therapeutics GmbH

Les Laboratoires Servier SAS

Pharmaxis Ltd

ProMetic Life Sciences Inc

Redx Pharma Plc

Regulus Therapeutics Inc

Sirnaomics Inc

Symic Biomedical Inc

Vascular Biogenics Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Kidney Fibrosis Overview

Kidney Fibrosis Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Kidney Fibrosis Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Kidney Fibrosis Companies Involved in Therapeutics Development

AdAlta Ltd

Angion Biomedica Corp

BiOrion Technologies BV

Cellmid Ltd

Epigen Biosciences Inc

Evotec AG

Galectin Therapeutics Inc

Genzyme Corp

Isarna Therapeutics GmbH

Les Laboratoires Servier SAS

Pharmaxis Ltd

ProMetic Life Sciences Inc

Redx Pharma Plc

Regulus Therapeutics Inc

Sirnaomics Inc

Symic Biomedical Inc

Vascular Biogenics Ltd

Kidney Fibrosis Drug Profiles

1D-11 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AD-214 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ANG-3070 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ANG-3586 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ANG-4201 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BMP-7 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BOT-191 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CAB-102 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CT-140 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs for Tissue Fibrosis Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fluorofenidone Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate Smad7 for Hypertensive Cardiomyopathy and Kidney Fibrosis Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GRMD-02 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IP-9 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ISTH-0047 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LJ-1888 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

melittin Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MSB-003 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MSB-014 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Oligonucleotides to Inhibit MIR199a for Fibrosis Drug Profile

Product Description

Mechanism Of Action

R&D Progress

P-007 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PAT-1251 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PAT-505 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PBI-4050 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PXS-4820 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PXS-5033A Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PXS-5338K Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PXS-5382A Drug Profile

Product Description

Mechanism Of Action

R&D Progress

REDX-06109 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RG-012 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SB-300 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Insulin-Regulated AminoPeptidase for Alzheimer’s Disease, Cardiac and Renal Fibrosis Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize Integrin for Kidney Fibrosis Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize LPA1 Receptor for Metastatic Breast Cancer and Renal Fibrosis Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Cyclophilin D for Obesity and Renal Fibrosis Drug Profile

Product Description

Mechanism Of Action

R&D Progress

STP-705 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Agonize AGTR2 for Kidney Fibrosis, Liver Fibrosis and Myocardial Fibrosis Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Agonize BMP7 Receptor for Renal Fibrosis Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TEW-7197 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VB-0004 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VB-201 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VB-4P5 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VB-703 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Wnt-001 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Kidney Fibrosis Dormant Projects

Kidney Fibrosis Discontinued Products

Kidney Fibrosis Product Development Milestones

Featured News & Press Releases

Nov 13, 2017: AdAlta to present at Anti-Fibrotic Drug Development Summit in Boston

Sep 06, 2017: Pharmaxis Announces Anti Fibrotic LOXL2 Program Clears Preclinical Development And Set To Commence Phase 1 Trials

Sep 04, 2017: AdAlta to present kidney fibrosis data at Australian and New Zealand Society of Nephrology Annual Scientific Meeting

Apr 25, 2017: Galectin Therapeutics Receives Notice of Japanese Decision to Grant a Composition of Matter Patent for GR-MD-02

Nov 18, 2016: ProMetic presents PBI-4050's positive effect on diabetic patients' kidneys at the American Society of Nephrology Annual Meeting

Jul 12, 2016: Galectin Therapeutics Receives Notice of Australian Patent to be Granted for the Use of GR-MD-02 in Liver, Kidney, Lung or Heart Fibrosis

Nov 12, 2015: Regulus Announces Grant of Patent Covering Lead microRNA Therapeutics

Nov 09, 2015: ProMetic's PBI-4050 data on renal fibrosis and pancreatic function featured at the American Society of Nephrology's annual meeting

Oct 29, 2015: ProMetic's PBI-4050 Cleared to Commence Clinical Trial in Patients With Type 2 Diabetes and Multi-Organ Fibrosis in Europe

Oct 05, 2015: Regulus to Present Additional Preclinical Data Supporting RG-012 as a Novel microRNA Therapeutic in Development for Alport Syndrome at ASN's Kidney Week 2015

Aug 13, 2015: Galectin Therapeutics Receives U.S. Patent Notice of Allowance for Use of Pectin Compounds to Reduce Fibrosis in Multiple Diseases

Oct 14, 2014: Regulus Therapeutics To Present New Preclinical Data on Multiple Programs At 10th Annual Oligonucleotide Therapeutics Society Meeting

Aug 05, 2014: Galectin Therapeutics Receives U.S. Patent for GR-MD-02 Composition of Matter

Jul 25, 2014: Galectin Therapeutics to Host Webcast to Discuss Findings From Cohort 2 of Phase 1 Clinical Trial of GR-MD-02 in Fatty Liver Disease With Advanced Fibrosis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Kidney Fibrosis, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Target, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Kidney Fibrosis Pipeline by AdAlta Ltd, H1 2018

Kidney Fibrosis Pipeline by Angion Biomedica Corp, H1 2018

Kidney Fibrosis Pipeline by BiOrion Technologies BV, H1 2018

Kidney Fibrosis Pipeline by Cellmid Ltd, H1 2018

Kidney Fibrosis Pipeline by Epigen Biosciences Inc, H1 2018

Kidney Fibrosis Pipeline by Evotec AG, H1 2018

Kidney Fibrosis Pipeline by Galectin Therapeutics Inc, H1 2018

Kidney Fibrosis Pipeline by Genzyme Corp, H1 2018

Kidney Fibrosis Pipeline by Isarna Therapeutics GmbH, H1 2018

Kidney Fibrosis Pipeline by Les Laboratoires Servier SAS, H1 2018

Kidney Fibrosis Pipeline by Pharmaxis Ltd, H1 2018

Kidney Fibrosis Pipeline by ProMetic Life Sciences Inc, H1 2018

Kidney Fibrosis Pipeline by Redx Pharma Plc, H1 2018

Kidney Fibrosis Pipeline by Regulus Therapeutics Inc, H1 2018

Kidney Fibrosis Pipeline by Sirnaomics Inc, H1 2018

Kidney Fibrosis Pipeline by Symic Biomedical Inc, H1 2018

Kidney Fibrosis Pipeline by Vascular Biogenics Ltd, H1 2018

Kidney Fibrosis Dormant Projects, H1 2018

Kidney Fibrosis Dormant Projects, H1 2018 (Contd..1), H1 2018

Kidney Fibrosis Discontinued Products, H1 2018

List of Figures

List of Figures

Number of Products under Development for Kidney Fibrosis, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Top 10 Routes of Administration, H1 2018

Number of Products by Stage and Top 10 Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1 2018

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports